TNX 1700
Alternative Names: mTNX-1700; Recombinant Trefoil Family Factor 2; rTFF2; TNX-1700; Trefoil Family Factor 2 - Tonix PharmaceuticalsLatest Information Update: 14 Jun 2024
At a glance
- Originator Columbia University
- Developer Columbia University; Tonix Pharmaceuticals Holding Corp
- Class Anti-inflammatories; Antineoplastics; Biological factors; Recombinant fusion proteins
- Mechanism of Action Trefoil factor-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Gastric cancer
- No development reported Pancreatic cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Gastric cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Nov 2023 Preclinical development in Gastric-cancer is ongoing in USA (Tonix Pharmaceuticals Holding Corp pipeline; November 2023)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Gastric-cancer in USA